Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.

Further robust studies are needed to elucidate the possible protective effect of aripiprazole. Long-term prospective studies are required for accurate appraisal of diabetes risk, hypertension and hyperlipidaemia in patients exposed to antipsychotic polypharmacy.